---
created: 2025-04-13
updated: 2025-04-13T10:53
id: icp8xCKTp|
specialty: cardio
specialty_id: 326
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::05-cardio::06-heart-failure::05-chronic-heart-failure
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::09-sacubitril
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::01-cardiology::02-heart-failure
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::01-hypertension-treatment
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::08-sacubitril
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::06-cardio::sacubitril
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::fa-cardio
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::1000-1999::1978
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::11000-11999::11745
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^expn::uworld
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::4-loweryield
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::01-cardiology::pharm::cvs-pharm-2"
type: flashcard
---

# Question
Sacubitril is an antiHAS neprilysin inhibitor that combined with **ARBs** = treatment of chronic **systolic** heart failure

---

# Answer
Therefore, a Neprilysin inhibitor (Sacubitril) = beneficial effect in HFrEF; Sacubitril acts on atrial and ventricular cardiomyocytes to inhibit neprilysin, enhancing ANP 'n' BNP activity == vasodilation and diuresis (excretion of Na+ and H2O)  Neprilysin, however, also inactivates ATII == deleterious vasoconstriction and fluid retention ~ inc ATII For this reason, tx of HFrEF = neprilysin inhibitor + ARB angiotensin II-receptor blocker (eg, sacubitril-valsartan) combined